![]()
Ozempic is not currently approved for kids but the medical industry wants to get there.
A new JAMA Pediatrics article argues that GLP-1 receptor agonists (the same class behind drugs like Ozempic/Wegovy) could be used more broadly in adolescents with obesity or related conditions. Early evidence suggests modest improvements in blood sugar, weight, and blood pressure. But even the authors admit they don’t know how to safely monitor or discontinue these drugs in young patients.
A recent study showed that most people who start these drugs quit within a year because the side effects are unbearable.
Why would they want to do this to children? Wouldn’t the ethical approach be to protect young people from a pharmaceutical treadmill that has no end?
Researchers ignore key questions about how these powerful metabolic drugs might affect puberty and long-term growth. And there’s still no protocol for safely going off them without rapid rebound — meaning these are maintenance drugs, not cures.
Maintenance drugs with hellish side effects including relentless nausea, diarrhea, vomiting, constipation, acid reflux.
Why would we put young people on that? Why would we normalize a lifetime of chemical management before they’re even done growing?